<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662958</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-LUT-201802</org_study_id>
    <nct_id>NCT03662958</nct_id>
  </id_info>
  <brief_title>Comparison of a Novel Leuprolide With Market Leuprolide</brief_title>
  <official_title>Evaluation of the Testosterone Suppressive Effect in Healthy Male Volunteers of a Novel Leuprolide Acetate 3.75mg Depot (Lutrate) VS Market Reference Leuprolide Acetate 3.75mg Depot (Enantone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose, randomized, single blind, parallel group study to evaluate the
      testosterone suppressive effect in healthy male volunteers of a novel leuprolide acetate
      3.75mg depot vs market reference leuprolide acetate 3.75mg depot. The safety, tolerability
      and the pharmacokinetic properties of the investigational drug and the control drug will also
      be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of castration at the end of week 4 (i.e. day 29)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to castration (i.e Tlag) between the 2 groups after administration of leuprolide</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of castration (i.e Tcast)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Local tolerability</measure>
    <time_frame>post-dose 5 min and 1 hour, day 8, 15 and 29</time_frame>
    <description>(10) Subjects will evaluate pain with VAS. Investigators will evaluate redness and induration with a 4-point scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>AE</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>pulse rate</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>respiratory rate</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>body temperature</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>body weight</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Lutrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a novel leuprolide acetate 3.75mg depot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enantone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>market reference leuprolide acetate 3.75 mg depot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutrate</intervention_name>
    <description>a novel leuprolide acetate 3.75mg depot</description>
    <arm_group_label>Lutrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enantone</intervention_name>
    <description>market reference leuprolide acetate 3.75 mg depot</description>
    <arm_group_label>Enantone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males of 18-40 years old (inclusive). The age difference of subjects within and
             between groups should be less than 10 years, at the time of screening.

          2. Body weight of at least 50kg. BMI to be 19-24 kg/m2 (inclusive).

          3. Able to comprehend the full nature and purpose of the study, including potential risks
             and side effects; able to cooperate with investigators and to comply with the
             requirements of the study

          4. Signed informed consent form prior to any screening procedures

        Exclusion Criteria:

          1. Clinically significant and relevant history of cardiovascular, hepatic, renal,
             hematologic, endocrine, respiratory, neurological diseases or acute/chronic diseases
             of the digestive tract.

          2. History of hypersensitivity towards leuprolide, synthetic LHRH or LHRH derivatives or
             any excipients of the study formulation.

          3. Abnormal and clinically significant 12-lead ECG

          4. Abnormal and clinically significant laboratory assessments

          5. Blood donation or blood loss greater than or equal to 400mL within 3 months prior to
             screening

          6. Participation of clinical trials within 3 months prior to screening

          7. Use of any drugs within 2 weeks prior to screening

          8. History of drug abuse within 1 year prior to screening

          9. History of alcohol abuse within 1 years prior to screening

         10. History of tobacco smoking (more than 5 cigarette per day) within 1 year prior to
             screening

         11. Abnormal testosterone level at screening (not in the range of 168-781ng/dL)

         12. Dermatitis or skin anomalies that might affect the administration area and the
             surroundings

         13. Subject or his partner not willing to adopt appropriate contraceptive measures

         14. Subjects have a history of depressive illness or sexual dysfunction;

         15. Subjects that the investigator deems unsuitable to be enrolled

         16. Subject not willing to cooperate with the investigators.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongju Wang, MD</last_name>
    <phone>0552-3086026</phone>
    <email>wanghongju@bbmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

